产品说明书

Yohimbine HCI

Print
Chemical Structure| 65-19-0 同义名 : Yohimbine (hydrochloride);Antagonil;Dayto himbin;Yoman;Yovital;Yohimar;Thybine;Actibine;Yohimbic acid methyl ester;Johimbin;Aphrosol;Aphrodyne;(+)-Yohimbine;APHRODINE;Yocon;Yohimex;Quebrachine;Quebrachin;Corynine;Yohimbin;Yohimbine;Yohimbe;NSC 19509;NIH 9689;Yohimbine HCl
CAS号 : 65-19-0
货号 : A137676
分子式 : C21H27ClN2O3
纯度 : 99+%
分子量 : 390.904
MDL号 : MFCD00012674
存储条件：

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 35 mg/mL(89.54 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 3 mg/mL(7.67 mM)，配合低频超声助溶
动物实验配方：
生物活性
靶点

  • α-adrenergic receptor
描述 Yohimbine hydrochloride is an α2 adrenergic receptor inhibitor. It blocks the α2 adrenergic receptor before or after synapse and causes the release of noradrenaline and dopamine. In vivo, yohimbine hydrochloride (0.2 mg/kg, i.p.) injected to rats 1h before the stress session daily for 14 consecutive days significantly increased the sexual arousal and potency and corrected the effects induced by stress on the mating behavior of male rats[3]. Moreover, increased noradrenergic activity after yohimbine administration and fear responses were higher after yohimbine as indicated by skin conductance responses and fear-potentiated startle responses[4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.79mL

2.56mL

1.28mL

25.58mL

5.12mL

2.56mL
参考文献

[1]Banihashemi L, Rinaman L. Noradrenergic inputs to the bed nucleus of the stria terminalis and paraventricular nucleus of the hypothalamus underlie hypothalamic-pituitary-adrenal axis but not hypophagic or conditioned avoidance responses to systemic yohimbine. J Neurosci. 2006 Nov 1;26(44):11442-53.

[2]Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998 Feb;159(2):433-6.

[3]Saad MA, Eid NI, Abd El-Latif HA, Sayed HM. Potential effects of yohimbine and sildenafil on erectile dysfunction in rats. Eur J Pharmacol. 2013;700(1-3):127-133.

[4]Kuehl LK, Deuter CE, Hellmann-Regen J, Kaczmarczyk M, Otte C, Wingenfeld K. Enhanced noradrenergic activity by yohimbine and differential fear conditioning in patients with major depression with and without adverse childhood experiences. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109751.